Clinical Trial Update: Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab plus R-CHOP as first-line treatment for diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-CHOP
• Sintilimab (sintilimab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Diffuse Large B-Cell Lymphoma, Sintilimab | Phase 2 | Status: UNKNOWN